Propel Bio Management’s Abeona Therapeutics ABEO Stock Holding History

Propel Bio Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.08M	Sell	983,070 -346,829	-26%	-$1.9M	3.18%	10
2026 Q1	$6.01M	Buy	1,329,899 +499,119	+60%	+$2.5M	3.79%	6
2025 Q4	$4.38M	Sell	830,780 -143,242	-15%	-$721K	3.74%	10
2025 Q3	$5.14M	Hold	974,022	–	–	5.15%	7
2025 Q2	$5.53M	Buy	974,022 +350,000	+56%	+$1.99M	6.71%	5
2025 Q1	$2.97M	Hold	624,022	–	–	3.45%	8
2024 Q4	$3.48M	Hold	624,022	–	–	3.45%	10
2024 Q3	$3.94M	Sell	624,022 -624,022	-50%	-$3.26M	2.29%	11
2024 Q2	$5.29M	Buy	+1,248,044	New	+$6.37M	3.43%	10

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OIA

OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Propel Bio Management's ABEO Position: Q2 2026 in Review

Propel Bio Management reduced its Abeona Therapeutics (ABEO) stake by 26% in Q2 2026, selling an estimated $1.9M and leaving 983,070 shares worth $6.08M. The position accounts for 3.18% of the portfolio, ranked #10.

Propel Bio Management first reported a position in ABEO in Q2 2024 and has held it in 9 quarters since. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

Propel Bio Management held 983,070 shares of Abeona Therapeutics worth $6.08M as of Q2 2026.
Propel Bio Management sold 346,829 Abeona Therapeutics shares in Q2 2026, an estimated $1.9M.
Abeona Therapeutics made up 3.18% of Propel Bio Management's portfolio in Q2 2026, its #10 holding.
Propel Bio Management first reported a position in Abeona Therapeutics in Q2 2024 and has held it in 9 quarters since.
126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.